Quantcast

Latest UCB Stories

2010-11-30 09:00:00

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam. Vimpat® tablets and injection were launched in the U.S. in May 2009 as an...

2010-11-22 11:03:00

ATLANTA, Nov. 22, 2010 /PRNewswire/ -- New stories and insights from the epilepsy community have been unveiled on EpilepsyAdvocate.com, including new interviews on "Women Succeeding with Epilepsy" and Epilepsy Advocate Radio. These programs represent UCB's continued commitment to the epilepsy community and seek to both empower patients and raise awareness about the condition. NEW WEBISODES FOR WOMEN! Two new video interviews are available featuring Epilepsy Advocates Amy Wyatt and...

2010-11-18 09:00:00

ATLANTA, Nov. 18, 2010 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Rheumatoid Arthritis Family Scholarship Program for outstanding individuals affected by this condition. UCB is awarding 31 scholarships worth up to $10,000 to help deserving students seek personal growth through higher education. The scholarship winners include rheumatoid arthritis (RA) patients, as...

2010-11-09 09:30:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- Today, UCB, Inc. celebrates the academic success of the 2010 UCB Family Epilepsy Scholarship recipients. Over the past 6 years, UCB has awarded more than 200 scholarships, totaling over $1 million, to people whose lives have been directly affected by epilepsy, including those with epilepsy, their caregivers and family members. Epilepsy is a common neurological condition that can affect anyone at anytime. In the United States, 1 in 100 people are...

2010-11-09 07:05:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: IMMU) announced that results from the phase IIb study, EMBLEM(TM), showed that certain doses of epratuzumab were associated with a meaningful and statistically significant* reduction in disease activity in adult patients with moderate to severe active SLE. The EMBLEM(TM) study was designed to evaluate the efficacy and safety of epratuzumab (in combination with immunosuppressants)...

2010-11-02 09:30:00

ATLANTA, Nov. 2, 2010 /PRNewswire/ -- UCB, a global biopharmaceutical company long recognized for its commitment to the epilepsy community and patient-centered approach, will mark Epilepsy Awareness Month by rolling out new activities and resources at the national and local levels. These programs represent UCB's continued commitment to the epilepsy community and seek to empower patients and raise awareness about the condition. For photos, videos and background information go to:...

2010-10-14 09:00:00

ATLANTA, Oct. 14 /PRNewswire/ -- UCB, Inc., a global leader in the research and development of medications to treat immunology disorders, today announced the winners of its 2010 UCB Crohn's and Me Scholarship Program for outstanding individuals affected by this condition. UCB has selected 31 winners to receive a scholarship worth up to $10,000 to help them seek personal growth through higher education. The scholarship winners include Crohn's disease patients, as well as family members...

2010-09-30 11:00:00

BRUSSELS, Sept. 30 /PRNewswire/ -- People with Parkinson's disease who used once-daily Neupro® (rotigotine) in the RECOVER trial achieved improvements in quality of life, in addition to previously reported beneficial effects on motor and non-motor symptoms. Data presented this week at the 2nd World Parkinson Congress in Glasgow, UK, showed that Neupro® provided clinically relevant improvements in PDQ-8 score. This is a self-administered health-related...

2010-09-28 10:30:00

ATLANTA, Sept. 28 /PRNewswire/ -- UCB today announced the first installment of the Crohn'sAdvocate(TM) Online Forum Series, a succession of interactive programs designed to connect, educate and empower those who are affected by Crohn's disease. Crohn's disease is a chronic, progressive and debilitating inflammatory bowel disease that results in an inflammation of the gastrointestinal tract. Many Americans living with Crohn's disease often feel isolated and limit social activities...

2010-09-21 08:30:00

ATLANTA, Sept. 21 /PRNewswire/ -- UCB, Inc., a global biopharmaceutical leader in the research and development of medications to treat serious conditions including immunology disorders and central nervous system conditions, is proud to support people living beyond the boundaries of Crohn's disease, rheumatoid arthritis (RA) and epilepsy through three unique scholarship programs. In five years, UCB has awarded more than 400 scholarships--totaling more than $3 million--to individuals...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related